Mon, Mar 2, 2015, 3:41 AM EST - U.S. Markets open in 5 hrs 49 mins


% | $
Quotes you view appear here for quick access.

Omeros Corporation (OMER) Message Board

Dooper55 16 posts  |  Last Activity: Feb 19, 2015 9:06 AM Member since: Dec 9, 2006
  • Reply to

    briefing release

    by evlradr Feb 19, 2015 8:14 AM
    dooper55 dooper55 Feb 19, 2015 9:06 AM Flag

    Certainly more than three .....
    "All patients in this study cohort received OMS721 and improvements were observed across TMA disease markers. The investigators treating all of these patients at different sites consider the improvements to be treatment-related and clinically meaningful."

  • Reply to

    two things I like on the news

    by evlradr Feb 19, 2015 7:15 AM
    dooper55 dooper55 Feb 19, 2015 7:31 AM Flag

    - The Company Agrees to Physician Request to Continue Treatment of Patients with aHUS -

    SEATTLE, Feb. 19, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has completed dosing of the low-dose cohort of patients in its ongoing Phase 2 clinical trial evaluating the efficacy and safety of OMS721, the lead human monoclonal antibody for its mannan-binding lectin-associated serine protease-2 (MASP-2) program, in treating thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain. All patients in this study cohort received OMS721 and improvements were observed across TMA disease markers. The investigators treating all of these patients at different sites consider the improvements to be treatment-related and clinically meaningful. Based on observations in this cohort, a European investigator has requested that Omeros provide extended access to OMS721 for compassionate use in his two study patients, both of whom suffer from atypical hemolytic uremic syndrome (aHUS), a form of TMA.

    In the clinical trial, the first cohort consisted of three patients treated with the lowest dose of OMS721. All three patients have aHUS. Platelet count, serum lactate dehydrogenase (LDH), and serum haptoglobin were measured as markers of disease activity. When compared to baseline levels, platelet counts improved in all patients. Serum LDH levels remained normal in one patient, substantially decreased to close to the normal range in another and remained elevated in the third. Haptoglobin improved in two patients, normalizing in one. Creatinine levels in the one patient with independent renal function also improved.

    (more in the full PR)

  • Reply to

    Excellent Omidria data to be presented in April

    by dooper55 Feb 16, 2015 12:54 PM
    dooper55 dooper55 Feb 16, 2015 4:02 PM Flag

    The mean area-under-the-curve (AUC) difference (standard error) in VAS scores between subjects treated with OMS302 vs subjects treated with placebo was -4.94 mm (0.77) (95% CI: -6.44 to -3.44, p less than 0.001). Significantly more OMS302 subjects were pain free (VAS=0) at all postoperative evaluations (26.0% vs 17.2 %, p=0.0012) and significantly less OMS302 subjects had moderate to severe pain (VAS=40) at any time point (7.2% vs 14.4%, p=0.0005; respectively). Additionally, analgesic use on day of surgery was significantly lower for OMS302 subjects compared to placebo subjects (27.5% vs 37.1 %, p=0.0019, respectively).

  • "Conclusion
    OMS302 was associated with significantly less postoperative ocular pain and pain medication use on day of cataract surgery or intraocular lens replacement. Use of OMS302 in these settings may improve overall patient satisfaction with these procedures."

  • Reply to

    Excellent Omidria data to be presented in April

    by dooper55 Feb 16, 2015 12:54 PM
    dooper55 dooper55 Feb 16, 2015 1:04 PM Flag

    Yahoo really misbehaving. I can't post the full results and conclusion. The results were very good. Substantially less pain and analgesic use following surgery when Omidria is used.

  • At World Cornea Conference VII in San Diego ....
    Reduction in Analgesic Use and Postoperative Ocular Pain With New Irrigating Solution During Cataract and IOL Replacement Procedures

    Monday, April 20, 2015: 3:11 PM

    Room 1B (San Diego Convention Center)

    Edward J. Holland, MD, Cincinnati Eye Institute, Cincinnati, OH, USA

    Alan S. Crandall, MD, John A. Moran Eye Center, Salt Lake City, Utah, USA

    Steve Whitaker, MD, Omeros Corporation, Seattle, WA, USA

    Post-hoc integrated analyses of subject-reported early postoperative pain and documented analgesic use following cataract and intraocular lens replacement (ILR) procedures – pooled data from three prospective, randomized controlled studies of OMS302 (Omidria [phenylephrine and ketorolac injection] 1%/0.3%).

    Data from 3 prospective, controlled, randomized clinical studies of OMS302 in subjects undergoing cataract extraction/replacement or refractive lens exchange surgery were included in a pooled post-hoc and integrated analysis of 1) early postoperative ocular pain and 2) analgesic use on the day of the procedure. Early postoperative ocular pain was assessed by each subject using a visual analog scale (VAS) at the following time points: 2, 4, 6, 8, and 10–12 hours after surgery. Analgesic use on day of surgery was recorded. A total of 919 subjects (461 placebo and 458 OMS302) were included.

    (see reply for Results and Conclusion)

  • New SC 13G/A filing today .........

    Item 4. Ownership.

    (a) Amount beneficially owned:


    (b) Percent of class:


    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

    Ingalls & Snyder, LLC ("I&S") is a registered broker dealer and a
    registered investment advisor. Shares reported under shared
    dispositive power include shares held in accounts managed under
    investment advisory contracts.

  • Omeros Closes $84 Million Public Offering of Common Stock and Pre-Funded Warrants

    SEATTLE, Feb. 3, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to investors on January 28, 2015 relating to the sale of 3,444,831 shares of its common stock at a price of $20.03 per share and 749,250 pre-funded warrants to purchase up to an equal number of shares of its common stock at a price per warrant of $20.02, which was paid at closing. The pre-funded warrants have an exercise price of $0.01 per share and will expire on February 3, 2022. Gross proceeds from the offering were approximately $84.0 million, including approximately $15.0 million from the sale of the pre-funded warrants. The closing also included the sale of 449,325 shares of common stock sold pursuant to the option allowing the underwriters to purchase additional shares of common stock from Omeros, which the underwriters exercised in full. After deducting underwriting discounts and other estimated offering expenses, Omeros will receive net proceeds from the transaction of approximately $79.1 million.

    Cowen and Company, LLC acted as the sole book-running manager for the offering.

    Wedbush PackGrow Life Sciences acted as co-lead manager. Needham & Company, LLC, Maxim Group LLC, WBB Securities LLC and MLV & Co. LLC acted as co-managers.

    A shelf registration statement (File No. 333-201581) relating to these securities (including the shares issuable upon the exercise of the pre-funded warrants) was filed with the Securities and Exchange Commission on January 16, 2015 and was automatically effective upon filing. A final prospectus supplement related to the offering was filed with the Securities and Exchange Commission on January 30, 2015.

    [More details in the full press release on the OMER website]

  • Reply to

    Last Day for Secondary

    by evlradr Feb 3, 2015 10:20 AM
    dooper55 dooper55 Feb 3, 2015 4:07 PM Flag

    OMER filed an 8-K yesterday (Monday). All of the shares, warrants and over allotment shares have been sold. Full listing in the 8-K.

  • This PharmacoSurgery product (a surgical irrigation solution additive) has demonstrated pain and inflammation reduction in arthroscopic surgeries. OMER is actively pursuing outlicensing OMS103. Since it is a combination of approved prescription medications, no further clinical trials or FDA approvals are needed. This could be quite significant because it could be used in many surgical situations, not just arthroscopic surgeries.

    And their newly improved financial position is a plus when bargaining with potential OMS103 licensors.

    All just FYI but, IMO, potentially a significant 2015 happening.

  • Reply to

    pricing of offering

    by stocktraderathome Jan 29, 2015 8:42 AM
    dooper55 dooper55 Jan 29, 2015 8:50 AM Flag

    I agree 100%.

  • Reply to


    by evlradr Jan 4, 2015 12:00 PM
    dooper55 dooper55 Jan 5, 2015 1:14 PM Flag

    Catalyst = approval of passthrough Medicare/insurance reimbursement of $465 per single use Omidria vial outside of the standard eye surgery bundle.

    And then there's OMER's strong pipeline.

    Sentiment: Buy

  • FWIW, I just found Omidria info on You may have seen it before. It's like the micro-print fact sheet contents that come with all prescription drugs. It even shows the vial packing box layout. I had to zoom to 300x+ to read that.

    Go to and search for Omidria

  • Commercial launch possible with Medicare/insurance reimbursements

  • Reply to

    Nice Comments

    by evlradr Dec 13, 2014 8:09 AM
    dooper55 dooper55 Dec 13, 2014 3:30 PM Flag

    I agree!

20.87-0.06(-0.29%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.